Faster TRD Remission: What Smarter Dosing Means for You

The News: Smarter, Faster Care for Treatment-Resistant Depression

A clinical commentary published this week in Psychiatric Times makes a pointed argument: when it comes to treatment-resistant depression (TRD), speed and precision matter more than most clinicians currently practice. The piece, "Optimizing the Use of More Efficacious Treatments in Treatment Resistant Depression," outlines a practical framework for getting patients to remission faster — one built on three core pillars: standardized symptom measurement, aggressive dose optimization, and proactive side-effect management.

The authors take direct aim at what they see as a persistent problem in psychiatric care: clinicians who wait too long between adjustments, use inadequate doses, or allow side effects to go unaddressed until a patient simply gives up on treatment. In a field where patients with TRD have often failed two or more antidepressant trials, that kind of passive approach has real human costs — prolonged suffering, lost productivity, and in serious cases, elevated suicide risk.

While the piece covers a range of efficacious treatments for TRD — including newer pharmacological options and neuromodulation approaches — the framework it proposes is especially relevant for patients considering or currently undergoing ketamine therapy, one of the most established rapid-acting interventions for treatment-resistant depression available today.

Why This Matters for Ketamine Patients Specifically

Ketamine and its FDA-approved derivative esketamine (Spravato) already occupy a unique position in TRD care: unlike traditional antidepressants that can take four to six weeks to show results, ketamine can produce measurable mood improvements within hours to days. That speed is a major reason patients with TRD — people for whom months of trial-and-error with SSRIs, SNRIs, and other agents has come up empty — often find ketamine compelling.

But the Psychiatric Times commentary points to something the ketamine field has quietly grappled with for years: even with a fast-acting treatment, the path to durable remission isn't automatic. Dosing still needs to be individualized. Symptom monitoring still needs to happen between sessions. And side effects — in ketamine's case, things like dissociation, transient blood pressure changes, or post-infusion grogginess — need to be addressed directly rather than minimized or ignored.

The article's emphasis on using validated symptom scales (like the PHQ-9 or MADRS) at regular intervals is particularly relevant here. Many ketamine clinics, especially those operating in the cash-pay, wellness-oriented space, don't routinely administer standardized depression assessments before and after each session. That means clinicians — and patients — may be flying blind when evaluating whether a course of treatment is actually working, plateauing, or needs adjustment.

For patients who have undergone an initial series of infusions and are now in a maintenance phase, this gap is especially consequential. Without objective tracking, it's easy to continue maintenance sessions out of habit rather than evidence of continued benefit — or conversely, to discontinue before a true therapeutic plateau has been reached.

The Dose Optimization Question

One of the more nuanced arguments in the Psychiatric Times piece is about dose adequacy. In the antidepressant world, this typically means pushing to the maximum tolerated dose before declaring a medication ineffective. In ketamine practice, the calculus is different but the underlying logic applies: not everyone responds to the standard 0.5 mg/kg IV infusion protocol, and some patients who appear to be non-responders may simply be under-dosed.

This is an area where the ketamine field lacks the kind of robust, large-scale trial data that informs antidepressant dosing guidelines. Protocols vary significantly between clinics — in dose, frequency, infusion duration, and adjunct medications. The good news is that experienced ketamine providers are increasingly attuned to the need for individualization. The less encouraging reality is that patients comparing clinics on price or convenience alone may end up in settings where protocols are one-size-fits-all and there's little appetite for adjustment.

For patients currently in treatment who feel they've partially responded but not reached remission, this commentary offers a useful frame: it's worth having an explicit conversation with your provider about whether dose or frequency adjustments have been considered, and on what basis the current protocol was chosen for you specifically.

Side Effects Aren't Just Inconveniences

The third pillar — proactive side-effect management — is worth dwelling on. In the context of ketamine, dissociation is the side effect that gets the most attention, but it's also frequently misunderstood. Some degree of dissociation is expected and, in some theoretical frameworks, may even be part of ketamine's mechanism of action. But significant dissociation that disrupts the treatment experience, causes anxiety, or leads patients to dread sessions is a different matter. Left unaddressed, it becomes a dropout driver.

The Psychiatric Times framework implicitly pushes back against clinicians who treat side effects as the patient's problem to manage. For ketamine providers, this means ensuring set and setting are optimized, that patients are adequately prepared for the dissociative experience, and that there are real options — including protocol modifications — if a patient is consistently distressed. It also means taking seriously the cardiovascular monitoring that responsible ketamine administration requires, rather than treating it as a box-checking exercise.

What to Look For in a Ketamine Provider

The framework laid out in this Psychiatric Times piece — measure, adjust, manage side effects — is a reasonable proxy for clinical rigor that patients can actually assess when choosing a ketamine provider. Before committing to a clinic or a course of treatment, it's worth asking:

• Do you use a standardized depression scale (like the PHQ-9, MADRS, or BDI) to track my symptoms before and after sessions?
• What's your protocol for adjusting dosing if I'm not responding as expected after the initial series?
• How do you handle side effects like significant dissociation, blood pressure changes, or post-session disorientation?
• What does follow-up look like between sessions — is there a clinician reviewing my progress, or am I largely on my own?

These aren't gotcha questions — any competent ketamine provider should have thoughtful answers. Clinics that can't or won't engage with them are telling you something important about how your care will be managed.

Treatment-resistant depression is, by definition, a condition that hasn't responded to standard approaches. That makes the quality of clinical oversight around newer, more efficacious treatments like ketamine even more important — not less. The Psychiatric Times commentary is a timely reminder that a powerful intervention, optimally applied, is far more likely to get patients to where they need to be than a powerful intervention delivered passively.